bpc-157 safety regulatory status fda updates around peptides can sound complex, but the key point bpc-157 human clinical trials evidence

References Journal of Pharmaceutical Drug Delivery Research (2022) Pawar K

Exogenous AAS inhibit endogenous testosterone production, and discontinuation of their use is often associated with a prolonged decrease in testosterone secretion ( The substances used in PCT are administered in the treatment of male hypogonadism unrelated to androgen abuse ( To restore endogenous testosterone, mainly aromatase inhibitors (AIs), selective estrogen receptor modulators (SERMs), and human chorionic gonadotropin (hCG) are used ( In the 2024 WADA Prohibited List ( Aromatase is an enzyme that converts testosterone to estradiol (the most potent estrogen form) and androstenedione to estrone ( The anti-estrogenic compounds mentioned in the WADA list can be divided into two groups: SERMs (bazedoxifene, clomiphene, cyclofenil, ospemifene, raloxifene, tamoxifen, and toremifene) and selective estrogen receptor degraders (SERDs), of which fulvestrant is a representative

Then 0.5 multiplied by 100 equals 50 units

For the foundational background on bacteriostatic water, see What Is Bacteriostatic Water

Breckas team have put thousands of patients on BPC-157 without a reported adverse event (source)

RR, 1.44